Medical tests

Bio-Rad Announces Partnership with Seegene for Molecular Diagnostic Testing Products

Retrieved on: 
Wednesday, June 30, 2021
Medical Supplies, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Science and technology, Articles, Technology, Laboratory techniques, Molecular biology, Biotechnology, Medical tests, Bio-Rad Laboratories, Real-time polymerase chain reaction, Molecular diagnostics, Polymerase chain reaction

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products.

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease molecular diagnostic products.
  • We look forward to working with Seegene to provide needed diagnostic testing products to U.S. markets, said Dara Wright, Bio-Rad EVP and President, Clinical Diagnostics.
  • Seegene assays offer multiplex real-time PCR detection and differentiation, with high sensitivity and specificity of up to seven targets in a single reaction.
  • These forward-looking statements include, without limitation, statements we make regarding the development and launch of new products and our expectations about our products.

Vivera Pharmaceuticals Partners with Areum Bio LLC and Access Bio, Inc. to Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests

Retrieved on: 
Wednesday, June 30, 2021
Medicine, Medical tests, Branches of biology, Life sciences, Medical terminology, Biotechnology, Areum, Chromatography, Molecular biology, Rapid antigen test, Rapid diagnostic test, COVID-19 rapid antigen test

The efficiency of the EUA-authorized point of care (POC) CareStart Rapid Antigen Test, coupled with Vivera's broad distribution capabilities, will ensure the greater ease of access to rapid diagnostic testing solutions.

Key Points: 
  • The efficiency of the EUA-authorized point of care (POC) CareStart Rapid Antigen Test, coupled with Vivera's broad distribution capabilities, will ensure the greater ease of access to rapid diagnostic testing solutions.
  • The distribution partnership between Vivera, Areum Bio, and Access Bio will help make rapid testing more readily available as quickly as possible.
  • "This co-branded collaboration marks a new strategic alliance for Vivera," said Paul Edalat, Chairman and CEO of Vivera Pharmaceuticals.
  • "This is a great opportunity for Areum Bio to partner with Vivera, a reputable pharmaceutical company, for the nationwide distribution of the CareStart COVID-19 Rapid Antigen Tests," said Dr. Jong Kim, President of Areum Bio.

Results of Research on Identification of Covid-19 Viruses Utilizing Advantest's nanoSCOUTER™ Fine Particle Measurement Instrument Published in Nature Communications

Nanotechnology, Articles, Health, Nanopore, Medical tests, Virus, Izon Science, Nanopore sequencing

A research group of the Institute of Scientific and Industrial Research at Osaka University is studying virus testing methods using the AI-based particle identification system developed by Aipore Inc.2 and the nanoSCOUTER.

Key Points: 
  • A research group of the Institute of Scientific and Industrial Research at Osaka University is studying virus testing methods using the AI-based particle identification system developed by Aipore Inc.2 and the nanoSCOUTER.
  • The results of this research3 can be expected to facilitate immediate diagnoses in hospitals as well as viral screening for large gatherings.
  • The nanoSCOUTER is a lightweight, desktop-sized fine particle measurement instrument that utilizes a precise nanopore (nanometer-scale pore) sensor module made with semiconductor manufacturing processes and Advantest's proprietary microcurrent measurement technology.
  • Using Advantest's nanoSCOUTER, Aipore has developed a solution for AI analysis of measurement data of bioparticles such as viruses and bacteria.

Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant

Retrieved on: 
Tuesday, June 29, 2021
Infectious diseases, Biotechnology, Health, Medical devices, Branches of biology, Medicine, Biology, Immunologic tests, Medical tests, Biotechnology, Chromatography, Molecular biology, Rapid antigen test, Affimer, Lateral flow test, Severe acute respiratory syndrome coronavirus 2

Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are commercially available in Europe.

Key Points: 
  • Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer and pre|CISION platforms, is pleased to announce that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are commercially available in Europe.
  • The AffiDX SARS-CoV-2 antigen lateral flow test has been evaluated with a small number of patient samples confirmed to be Delta variant positive and, for a Ct
  • The AffiDX SARS-CoV-2 antigen lateral flow test is CE marked for professional use in the UK and EU.
  • Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: We are delighted to report that the AffiDX SARS-CoV-2 antigen lateral flow test detects the Delta variant with very high sensitivity for patients with a Ct value of less than 29.

OTC/DTC Infectious Disease Diagnostics 2020 to 2024: Rapid Testing Solutions Set to Help Solve Pandemic Problem - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021
Health, General Health, Medical tests, Applied Food Technologies

Over the Counter and Direct to Consumer diagnostics set to help solve the pandemic problem.

Key Points: 
  • Over the Counter and Direct to Consumer diagnostics set to help solve the pandemic problem.
  • New technologies create rapid test solutions for the home market.
  • Now infectious disease testing is moving directly to the consumer.
  • New sampling technology, rapid and multiplex tests have changed the picture on how and where testing is done.

Global Contrast Media Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Friday, June 25, 2021
Medical Supplies, Health, Medical physics, Radiology, Medicine, Radiation, Medical imaging, Applied sciences, Medical tests, CT scan, Multidimensional signal processing, Magnetic resonance imaging, X-ray, Contrast agent

The "Contrast Media Market Share, Size, Trends, Industry Analysis Report, By Application; By Product; By Modality; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Contrast Media Market Share, Size, Trends, Industry Analysis Report, By Application; By Product; By Modality; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global contrast media market size is expected to reach USD 5.33 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • Contrast media are used to improve internal images produced by MRI, CT scans, X-rays and allows radiologists to the difference between normal and diseased tissues.

Concert Genetics Unveils Comprehensive Genetic Test Identification System to Enable Automation in Precision Medicine

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Medical genetics, Software testing, Medicine, Medical tests, Test management, Automation, Genetic testing, g factor, Tests

NASHVILLE, Tenn., June 24, 2021 /PRNewswire/ --Concert Genetics has released its comprehensive genetic test identification system for use in the market, enabling a level of automation in test ordering, coverage, payment and clinical decision support never before possible, the company announced today.

Key Points: 
  • NASHVILLE, Tenn., June 24, 2021 /PRNewswire/ --Concert Genetics has released its comprehensive genetic test identification system for use in the market, enabling a level of automation in test ordering, coverage, payment and clinical decision support never before possible, the company announced today.
  • Initially developed as an internal test tracking system, Concert's GTUs have powered the company's widely used, end-to-end genetic test management solutions, becoming essential infrastructure for precision medicine in the process.
  • Today, they become available to the market at a time when the need for reliable test identification is more urgent than ever.
  • For example, disagreements between health plans and laboratories about test reimbursement often arise from the codes used to bill the test.

Infinity BiologiX and Cytox Collaborate to Provide New Genetic Test to Predict the Risk of Cognitive Decline Due to Alzheimer’s Disease

Retrieved on: 
Wednesday, June 23, 2021
Health, Genetics, General Health, Clinical trials, Research, Science, Biotechnology, Medicine, Branches of biology, Clinical medicine, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Medical genetics, Medical tests, Genetic testing, Alzheimer's disease, Disease, Dementia, Infinity BiologiX (IBX):, Cytox, genoSCORE™, INFINITY BIOLOGIX (IBX):, CYTOX, GENOSCORE™

Today, Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimers through a simple saliva or blood sample.

Key Points: 
  • Today, Infinity BiologiX, LLC (IBX) and Cytox Ltd, announce a collaboration to provide a new, non-invasive, genetic test that can predict the risk of cognitive decline due to Alzheimers through a simple saliva or blood sample.
  • Dr. Richard Pither, CEO of Cytox, commented: Alzheimers disease affects over 46 million people in the world1.
  • genoSCORE is a new non-invasive, genetic test to predict future risk of cognitive decline due to Alzheimers disease (AD).
  • This test is a measure of relative risk for future onset of Late-onset Alzheimers disease (LOAD) and should not be considered as standalone diagnostic test.

Dr. Peter Bach Joins Delfi Diagnostics as Chief Medical Officer

Retrieved on: 
Wednesday, June 23, 2021
Medicine, Clinical medicine, Cancer screening, Lung cancer, Medical tests, Lung cancer screening, Liquid biopsy, Screening, Cancer, Biopsy, Molecular diagnostics

BALTIMORE, June 23, 2021 /PRNewswire/ --Delfi Diagnostics, a developer of next-generation high performance, affordable liquid biopsy tests for early cancer detection, announced today that Peter B. Bach, MD, a lung cancer screening pioneer and health economics expert, has joined as Chief Medical Officer.

Key Points: 
  • BALTIMORE, June 23, 2021 /PRNewswire/ --Delfi Diagnostics, a developer of next-generation high performance, affordable liquid biopsy tests for early cancer detection, announced today that Peter B. Bach, MD, a lung cancer screening pioneer and health economics expert, has joined as Chief Medical Officer.
  • Dr. Bach created the first lung cancer risk prediction model, and such models are now widely used to predict the likelihood of heavy smokers developing lung cancer.
  • He led numerous lung cancer screening guideline panels, and as a private citizen initiated the request to Medicare that resulted in nationwide coverage of lung cancer screening.
  • Founded in 2019, Delfi Diagnostics is committed to developing high-performing, affordable blood tests for early detection of cancer across multiple tumor types.

Europe In-Vitro Diagnostics Market Forecast Report 2021-2027: Increasing Adoption and Popularity of Automation in Clinical Laboratories - ResearchAndMarkets.com

Retrieved on: 
Monday, June 21, 2021
Health, Biotechnology, Alternatives to animal testing, In vitro, Natural sciences, Life sciences, Medical tests, Science

The in-vitro diagnostics market has accounted for a significant market share in the healthcare industry during the COVID-19 pandemic.

Key Points: 
  • The in-vitro diagnostics market has accounted for a significant market share in the healthcare industry during the COVID-19 pandemic.
  • Thus, such instances are significantly driving the Europe in-vitro diagnostics market and it is expected to continue in the following years.
  • The Europe in-vitro diagnostics market is segmented on the basis of product and services, technology, application, and end user.
  • Therefore, these countries have significantly contributed to the growth of the Europe in-vitro diagnostics market.